Truffle Capital — Full Portfolio

4 tracked investments · listed companies and verified rows first

VaxinMar 2015SEC filingmedium confidence

BiotechGaithersburg, US

Scot Roberts(Executive Officer)William Enright(Executive Officer, Director)

BoardFlorent Gros(Director)Philip Hodges(Director)Marten Steen(Director)

Board seatPhilippe Pouletty· per SEC Form D · $16M raise · filed Mar 2015

Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.

BiotechHealthtechMedical Devices

Co-investorsAndera Partners Claret Capital Partners Medicxi Samsara BioCapital Sofinnova Partners

Carvolixcarvolix.eu in

Carvolix develops AI- and imaging-driven mini-robotic technologies that assist interventional cardiologists during cardiac valve replacement and ischemic stroke (thrombectomy) procedures.

AI & Machine LearningMedical DevicesRobotics

Obatobat.fr in 𝕏Nov 2023

OBAT is a French SaaS for construction and building trades (BTP) professionals and artisans, offering tools for quotes, invoicing, electronic invoicing compliance, accounting export, and project/site management.

Construction TechFintechSaaS

Co-investorsIsai ISAI Gestion Kima Ventures Evolem Holnest

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.